Abbott India’s shares surged 2.12% to ₹28,120.00 on Tuesday afternoon, adding to its presence in the Nifty Midcap 150 index.
For the year ending March 2026, the company reported standalone sales of ₹6,929 crore, up from ₹6,409 crore in the previous year. Total income rose to ₹7,217 crore from ₹6,684 crore, while net profit increased to ₹1,552 crore compared with ₹1,414 crore in FY 2025.
In the quarter ending March 2026, Abbott India earned standalone sales of ₹1,709 crore. Adding other income of ₹75 crore, total income reached ₹1,785 crore. Net profit for the quarter stood at ₹394 crore.
Cash flow from operating activities was ₹1,319 crore for FY 2026. Investing activities saw a cash outflow of ₹371 crore, and financing activities produced an outflow of ₹1,066 crore, resulting in a net cash flow of –₹118 crore.
As of March 2026, total liabilities were ₹6,501 crore, with reserves and surplus at ₹4,752 crore and current liabilities at ₹1,476 crore. Total assets matched liabilities at ₹6,501 crore, comprising current assets of ₹3,770 crore and fixed assets of ₹336 crore.
Abbott India’s basic and diluted EPS for FY 2026 were both ₹730.36. The company posted a gross profit margin of 31.46%, operating margin of 30.36%, and net profit margin of 22.39%. Its price‑to‑earnings ratio stood at 35.48, while the price‑to‑book ratio was 11.54.
Upcoming corporate actions include a board meeting on 12 August 2026 to approve unaudited results for the quarter ended 30 June 2026. The company announced a final dividend of ₹525.00 per share and a special dividend of ₹131.00 per share, both payable on 24 July 2026. Historically, Abbott India has issued bonus shares; the latest was a 1:1 bonus on 10 August 1998.
With its current trading price and strong financial performance, Abbott India continues to demonstrate robust growth and active corporate governance.